Total trials
93
Active
25
Phase 3
45
Total enrollment
14,470
Pipeline matrix
Showing 40 of 49 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Divozilimab | — | — | — | — | 4 | ||
| BCD-217 | — | — | — | — | 3 | ||
| BCD-263 | — | — | — | — | 2 | ||
| Opdivo | — | — | — | — | 2 | ||
| BCD-100 | — | — | — | 8 | |||
| BCD-131 | — | — | — | 3 | |||
| BCD-264 | — | — | — | — | 2 | ||
| Darzalex | — | — | — | — | 2 | ||
| BCD-178 | — | — | — | — | 2 | ||
| Perjeta | — | — | — | — | 2 | ||
| Levilimab | — | — | — | — | — | 2 | |
| Mircera | — | — | — | — | 2 | ||
| Adalimumab | — | — | — | — | 2 | ||
| anti-PD1 | — | — | — | — | — | 1 | |
| BCD-281 | — | — | — | — | — | 1 | |
| Ocrelizumab | — | — | — | — | — | 1 | |
| Netakimab | — | — | — | — | — | 1 | |
| anti-TRBV9 monoclonal antibody infusions | — | — | — | — | — | 1 | |
| Adalimumab subcutaneous | — | — | — | — | — | 1 | |
| ANB-002 | — | — | — | — | — | 1 | |
| anti-TL1A monoclonal antibody, low dose | — | — | — | — | — | 2 | |
| anti-TL1A monoclonal antibody, medium dose | — | — | — | — | — | 2 | |
| anti-TL1A monoclonal antibody, high dose | — | — | — | — | — | 2 | |
| BCD-248 | — | — | — | — | — | 1 | |
| BCD-236 | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| ANB-004, dose 1 | — | — | — | — | — | 1 | |
| ANB-004, dose 2 | — | — | — | — | — | 1 | |
| ANB-004, dose 3 | — | — | — | — | — | 1 | |
| ANB-002, dose 1 | — | — | — | — | — | 1 | |
| ANB-002, dose 2 | — | — | — | — | — | 1 | |
| ANB-002, dose 3 | — | — | — | — | — | 1 | |
| anti-TRBV9 monoclonal antibody, low dose | — | — | — | — | — | 1 | |
| anti-TRBV9 monoclonal antibody, high dose | — | — | — | — | — | 1 | |
| ANB-010, dose 1 | — | — | — | — | — | 1 | |
| ANB-010, dose 2 | — | — | — | — | — | 1 | |
| ANB-010, dose 3 | — | — | — | — | — | 1 | |
| BCD-256 | — | — | — | — | — | 1 | |
| Adalimumab (BCD-057) 100 mg/mL | — | — | — | — | — | 1 | |
| Adalimumab (BCD-057) 50 mg/mL | — | — | — | — | — | 1 |
9 more active programs hidden
Next readouts
- 2024-01-31
- 2024-06-20
- 2024-09
- 2024-10-01
- 2024-12
- 2025-01
- 2025-01
- 2025-02
- 2025-06-06
- 2025-09
Top conditions
- Healthy12
- Melanoma7
- Rheumatoid Arthritis5
- Multiple Sclerosis5
- Melanoma (Skin)4
- Ankylosing Spondylitis4
- Hepatitis3
- Hepatitis C3
Frequently asked questions about Biocad
- How many clinical trials does Biocad have on ClinicalTrials.gov?
- Biocad is listed as the lead sponsor on 93 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Biocad's trials are in Phase 3?
- 45 of Biocad's trials are in Phase 3, spread across 49 active drug programs.
- What therapeutic areas does Biocad focus on?
- Biocad's most-studied conditions on ClinicalTrials.gov are Healthy, Melanoma, Rheumatoid Arthritis, Multiple Sclerosis, Melanoma (Skin).
- When are Biocad's next clinical trial readouts?
- Biocad has 10 upcoming primary-completion readouts tracked here; the soonest is “A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin”, expected around 2024-01-31.